Fenfluramine for Lennox-Gastaut Syndrome: Long-Term Efficacy, Safety, and Outcomes Beyond Seizure Reduction
From Neurology: Disease Deep Dive · 12:02
Show by Practical Neurology
How quickly does fenfluramine improve seizure control in patients with Lennox-Gastaut syndrome (LGS), and how do its efficacy and safety outcomes evolve over time? In this episode, Amélie Lothe, PhD, Global Medical Head, Rare Epilepsies and Neurodevelopmental Disorders, UCB, and coauthor of a recent study published in Epilepsia Open, discusses findings from a post hoc analysis of a phase 3 fenfluramine clinical trial and its open-label extension. Source: Nabbout R, Devinsky O, Lagae L, et al. Changes in effectiveness and safety in patients with Lennox-Gastaut syndrome transitioning from the fenfluramine randomized controlled trial to open-label extension study. Epilepsia Open. 2026 Oct;11:1871-1879. doi: 10.1002/epi4.70320.
More episodes of Neurology: Disease Deep Dive
More episodes
- What's New in Migraine Prevention? Understanding the 2026 AAN/AHS Guidelines
- Rethinking Multiple Sclerosis: A New Biologic Framework for MS Progression
- Narcolepsy, Idiopathic Hypersomnia, and General Sleep Disorders
- NMOSD Part 1 - Overview and important considerations for diagnosis
- NMOSD Part 2 - The importance and tools for monitoring NMOSD, and signs, symptoms and evaluation of disease activity
- NMOSD Part 3 - Overview of treatment, including goals, triggers, and considerations for switching therapies
- Advances in the Evaluation of TBI
- The Evolving Therapeutic Landscape for Parkinson Disease
- Cerebrovascular Inflammatory Conditions: Diagnostic Challenges and Treatment Considerations
- Advances in ALS: New Targets, Trials, and Care Strategies
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.